Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2013-04-19 / Cancer Immunol. Immunother. 2013 Jun;62(6):1083-91Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer
/in Dendritic Cells, International Publications, SCLC /von 2013-04-16 / Cancer Immunol. Immunother. 2013 May;62(5):909-18Hyperthermia versus Oncothermia: Cellular Effects in Complementary Cancer Therapy
/in Hyperthermia, International Publications /von 2013-04-14 / Evid Based Complement Alternat Med 2013;2013:672873Science kürt Immuntherapie gegen Krebs 2013 zum „Breakthrough of the Year“
/in Externe Meldungen /von IOZK
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution